Ask a Question
Respected Doctor, You may share your queries here. Doctor will address it at the end of session. Thank You.
15 Comments
Leave a Reply
15 Comments
-
Anonymous Side effects of simaglitin
-
Anonymous Apart from weight loss, what are the other mechanisms by which Semaglutide is helpful in MASH ?
-
Anonymous Good evening sir
-
Anonymous Can it be use in MASH with Pregnancy?If yes, in which trimester and in what dose and duration?
-
Anonymous Outstanding session
-
Anonymous OK
-
Anonymous Can we use in OSA/ weight loss
-
Anonymous Effect of Semaglutide on ckd patients
-
Anonymous 1. Do you think lower doses of Semaglutide (since in a few of your slides there were doses of 0/1, 0.2, and 0.4mg) could still offer clinically meaningful benefits in steatosis and fibrosis, particularly in populations where full-dose escalation may not be feasible?
2. Considering Asia’s unique phenotype, including higher lean MASLD prevalence and early-onset diabetes, do you expect different responses to semaglutide compared to Western populations?
3. From your experience, what are the key practical challenges in implementing the stepwise dose escalation of semaglutide in routine clinical practice globally? -
Anonymous What’s the dose like for MASH?
-
Anonymous Is there any role for semaglutide in compensated and decompensated CLD secondary to MASH?
-
Anonymous Please comment on the risk of optic neuritis and pancreatitis with semiglutide
-
Anonymous sub-therapeutic doses can still provide clinically meaningful improvements in steatosis or fibrosis, especially for patients who cannot tolerate full-dose escalation?
-
Anonymous Thank you Sir for Mentioning us 🙏
-
Anonymous .
Side effects of simaglitin
Apart from weight loss, what are the other mechanisms by which Semaglutide is helpful in MASH ?
Good evening sir
Can it be use in MASH with Pregnancy?If yes, in which trimester and in what dose and duration?
Outstanding session
OK
Can we use in OSA/ weight loss
Effect of Semaglutide on ckd patients
1. Do you think lower doses of Semaglutide (since in a few of your slides there were doses of 0/1, 0.2, and 0.4mg) could still offer clinically meaningful benefits in steatosis and fibrosis, particularly in populations where full-dose escalation may not be feasible?
2. Considering Asia’s unique phenotype, including higher lean MASLD prevalence and early-onset diabetes, do you expect different responses to semaglutide compared to Western populations?
3. From your experience, what are the key practical challenges in implementing the stepwise dose escalation of semaglutide in routine clinical practice globally?
What’s the dose like for MASH?
Is there any role for semaglutide in compensated and decompensated CLD secondary to MASH?
Please comment on the risk of optic neuritis and pancreatitis with semiglutide
sub-therapeutic doses can still provide clinically meaningful improvements in steatosis or fibrosis, especially for patients who cannot tolerate full-dose escalation?
Thank you Sir for Mentioning us 🙏
.